ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Amlodipine

Also written as “amlodipine”, “Amlodipine 5 mg” and “Amlodipine 10 mg”.

Its studies are mostly in Hypertension · Essential Hypertension · Hyperlipidemias · Kidney Diseases · Hypercholesterolemia, led by 35 companies.

Drug pageAmlodipine: every studyMany companies study it; this page follows only the 170 they lead. All 284 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 25, 2005170 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only570 open or runningphase 4since Aug 25, 2005Aug 25, 2005none ahead
Boehringer Ingelheimits history only220 open or runningphase 4since Oct 14, 2005Oct 14, 2005none ahead
Viatrisits history only130 open or runningphase 4since Aug 31, 2005Aug 31, 2005none ahead
Hanmi Pharmaceutical110 open or runningphase 3since Jul 14, 2009Jul 14, 2009none ahead
Dr. Reddy's Laboratoriesits history only80 open or runningphase 1since May 26, 2010May 26, 2010none ahead
HK inno.Nits history only50 open or runningphase 3since Feb 16, 2015Feb 10, 2014none ahead
Handokits history only40 open or runningphase 3since Jul 24, 2022Jul 21, 2020none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Feb 9, 2009Feb 9, 2009none ahead
Yuhanits history only41 open or runningphase 4since Sep 4, 2023May 29, 2014none ahead
Chong Kun Dang Pharmaceuticalits history only30 open or runningphase 3since Jan 8, 2016Feb 14, 2014none ahead

Also a collaborator on its studies: CSPC Pharmaceutical Group and Integrium.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hanmi Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2009First studies: 2 phase 3 studies in HypertensionFirst studyNCT00940667, NCT00940680
  2. Jul 17, 2009Phase 2 study in HypertensionNCT00942344 · 320 enrolled · Korea, Republic of
  3. May 19, 2010Phase 3 study in HypertensionNCT01127217 · 149 enrolled · Korea, Republic of
  4. Sep 7, 20102 phase 1 studies in HealthyNCT01197014, NCT01197001
  5. Aug 24, 2014Phase 1 study in HealthyNCT02243319 · 24 enrolled · Korea, Republic of
  6. Dec 17, 2014Phase 1 study in HypertensionNCT02387554 · 33 enrolled · Korea, Republic of
  7. Sep 9, 2016Phase 3 study in HypertensionNCT02899455 · 146 enrolled · Korea, Republic of
  8. Sep 2, 20192 phase 1 studies in HealthyNCT04081844, NCT04322266

TargetBeta

“Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
PregabalinruleViatrisphase 4149
GabapentinruleViatrisphase 449
DronedaroneruleSanofiphase 418
NifedipineruleBayerphase 418

Studies

All 11 Hanmi Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04322266Healthy · Korea, Republic of1CompletedFeb 13, 201961
NCT04081844Healthy · Korea, Republic of1CompletedJun 28, 201831
NCT02899455Hypertension · Korea, Republic of3CompletedJun 2016146
NCT02387554Hypertension · Korea, Republic of1CompletedOct 201433
NCT02243319Healthy · Korea, Republic of1CompletedDec 201424
NCT01197014Healthy · Czech Republic1CompletedNov 201072
NCT01197001Healthy · Czech Republic1CompletedOct 201072
NCT01127217Hypertension · Korea, Republic of3CompletedMar 2010149
NCT00942344Hypertension · Korea, Republic of2CompletedDec 2007320
NCT00940680Hypertension · Korea, Republic of3CompletedNov 2008142
NCT00940667Hypertension · Korea, Republic of3CompletedDec 2008185

How it is read

Names in the registry

  • “Amlodipine”, 44 entries
  • “amlodipine”, 14 entries
  • “Amlodipine 5 mg”, 9 entries
  • “Amlodipine 10 mg”, 6 entries
  • “valsartan + amlodipine”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.